Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
Results Announcement for the third quarter 2016
GSK delivers sales growth, improved cash flow and sustained pipeline progression in Q3.
Read more -
GSK announces US regulatory submission of candidate vaccine for prevention of shingles
Regulatory submissions in the EU and Canada remain on track for 2016
Read more -
New data published for GSK’s Nucala investigating hospitalisation reduction in severe asthma patients with an eosinophilic phenotype
The risk of hospitalisations or emergency room visits caused by asthma attacks was halved (51% reduction p<0.001) in severe asthma patients
Read more -
GlaxoSmithKline plc appoints Brian McNamara as CEO of GSK Consumer Healthcare
Brian join GSK’s Corporate Executive Team and will continue as a member of the Board of the Consumer Healthcare Joint Venture with Novartis.
Read more -
GlaxoSmithKline completes sale of remaining Aspen shares
GSK has agreed to the sale of 28.2 million ordinary shares in Aspen Pharmacare Holdings Ltd ("Aspen") at a price of ZAR 300 per share.
Read more -
GlaxoSmithKline announces intention to sell remaining holding in Aspen
GSK intends to sell its remaining stake in Aspen Pharmacare Holdings Ltd ("Aspen").
Read more -
GSK announces US regulatory submission for sirukumab in rheumatoid arthritis
Sirukumab is being co-developed for RA as part of a collaboration with Janssen Biologics (Ireland) [Janssen], an affiliate of JBI.
Read more -
GSK announces regulatory submissions for subcutaneous formulation of Benlysta® (belimumab) for patients with systemic lupus disease
It has filed regulatory submissions in the US and Europe for Benlysta® (belimumab) for approval.
Read more -
Emma Walmsley to succeed Andrew Witty as Chief Executive Officer of GlaxoSmithKline
Emma Walmsley, currently CEO of GSK’s Consumer Healthcare division, is appointed GSK CEO Designate and will succeed Andrew Witty as GSK CEO.
Read more -
GSK sets out further steps to address emerging global health security challenges
GSK will set out a series of steps to further address emerging global health challenges
Read more -
GSK’s candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM
GSK on track to file regulatory applications in 2016
Read more -
GSK announces EU regulatory submission for sirukumab in rheumatoid arthritis
Sirukumab is being co-developed for RA as part of a collaboration with Janssen Biologics (Ireland) [Janssen].
Read more -
GSK divests non-core assets to Aspen
A series of agreements Between Aspen and GSK through focusing on core therapeutic areas
Read more -
GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress
Improvements in lung function and health-related quality of life supported by statistically significant reductions in exacerbations
Read more -
‘Real world’ data shows 83 percent effectiveness for Bexsero® in infants in first year of UK national meningitis B immunisation programme
Cases of meningitis B halved after ten months
Read more -
GSK announce positive results from the COPD Salford Lung Study published in the NEJM and presented at European Respiratory Congress
The results from the pioneering Salford Lung Study (SLS) have been published in the New England Journal of Medicine (NEJM).
Read more -
NEJM publishes results of GSK’s long-term LABA safety study of Advair® Diskus® in children aged 4-11 years with asthma
Headline results reported in March, demonstrated that the study had achieved its primary endpoint.
Read more -
GSK’s continued commitment to innovative respiratory research demonstrated in European Respiratory Society congress data presentations
More than 30 abstracts from the company will be featured at the meeting.
Read more -
ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment
HIV care is a long-term prospect for those living with the disease, requiring life-long adherence to treatment.
Read more -
GSK and Verily to establish Galvani Bioelectronics – a new company dedicated to the development of bioelectronic medicines
GSK will hold a 55% equity interest in the new jointly owned company and Verily will hold 45%.
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
